[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100640505":3},{"organization":4,"outcomesModule":7,"designInfo":63,"detailedDescription":66,"studyPopulation":66,"armGroups":69,"interventions":82,"overallOfficials":66,"centralContacts":97,"locations":66,"responsibleParty":103,"collaborators":66,"id":107,"slug":66,"hasResults":108,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":112,"eligibilityCriteria":113,"healthyVolunteers":108,"sex":114,"minAge":115,"maxAge":66,"enrollmentInfo":116,"targetDuration":66,"studyType":119,"phases":120,"briefSummary":122,"conditions":123,"keywords":66,"overallStatus":125,"whyStopped":66,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":66},{"fullName":5,"class":6},"The Third Xiangya Hospital of Central South University","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":21,"otherOutcomes":44},[9,13,17],{"measure":10,"description":11,"timeFrame":12},"Proportion of Participants Completing All DCT Procedures from Remote Informed Consent to Last Visit","Proportion of enrolled participants who successfully complete all predefined decentralized clinical trial (DCT) procedures, including remote informed consent, electronic data capture, device connectivity, direct-to-patient drug delivery, scheduled follow-ups, and last study visit.","through study completion, an average of 5 months",{"measure":14,"description":15,"timeFrame":16},"Reliability Evaluation","Implementation Rate of the DP-DCT Platform Function List: A digital intelligent clinical research platform that achieves full-process digitalization from participant recruitment to statistical reporting, along with technologies such as real-time generation of certified electronic copies of key data, must possess the following functions and meet the relevant assessment indicators.","From study start to study completion (up to 24 months)",{"measure":18,"description":19,"timeFrame":20},"Clinical Study Evaluation Indicators","Difference between the two groups in the change of HbA1c from baseline after 12 weeks of treatment.\n\nChange from baseline\u002Frun-in period in Time in Range (TIR, 3.9-10 mmol\u002FL) between the two groups.","Baseline to Week 12",[22,26,29,31,33,35,37,40,42],{"measure":23,"description":24,"timeFrame":25},"Key Secondary Outcome Measure: HbA1c Key Secondary Outcome Measure","Proportion of participants in each group with HbA1c \\\u003C7% after 12 weeks of treatment.","Week 12",{"measure":23,"description":27,"timeFrame":28},"Proportion of participants in each group with HbA1c \\\u003C6.5% after 12 weeks of treatment.","week 12",{"measure":23,"description":30,"timeFrame":28},"Proportion of participants in each group with a reduction in HbA1c of ≥0.5% from baseline after 12 weeks of treatment.",{"measure":23,"description":32,"timeFrame":28},"Proportion of participants in each group with a reduction in HbA1c of ≥1% from baseline after 12 weeks of treatment.",{"measure":23,"description":34,"timeFrame":28},"Proportion of participants in each group with either a reduction in HbA1c of ≥1% from baseline or an HbA1c \\\u003C7.0% after 12 weeks of treatment.",{"measure":23,"description":36,"timeFrame":28},"Change from baseline in fasting serum glucose (FPG) after 12 weeks of treatment.",{"measure":38,"description":39,"timeFrame":28},"Key Secondary Outcome Measure: HbA1c Key Secondary Outcome Measure: CGM Metrics","Change from baseline\u002Frun-in period to the CGM follow-up period in Time Above Range (TAR, ≥10 mmol\u002FL) between the two groups.",{"measure":38,"description":41,"timeFrame":28},"Change from baseline\u002Frun-in period to the CGM follow-up period in Time Below Range (TBR, \\\u003C3.9 mmol\u002FL) between the two groups.",{"measure":38,"description":43,"timeFrame":28},"Comparison of the coefficient of variation (CV) of glucose",[45,48,51,54,57,60],{"measure":46,"description":47,"timeFrame":28},"Other exploratory endpoints：Proportion of patients achieving ≥5% or ≥10% body weight reduction from baseline","Proportion of patients achieving ≥5% reduction from baseline in body weight at 12 weeks, and proportion achieving ≥10% reduction.",{"measure":49,"description":50,"timeFrame":28},"Other exploratory endpoints：Change from Baseline in Fasting Serum Insulin","Change from baseline in fasting serum insulin level after 12 weeks of treatment.",{"measure":52,"description":53,"timeFrame":28},"Other exploratory endpoints：Change from Baseline in Serum C-Peptide","Change from baseline in serum C-peptide level after 12 weeks of treatment.",{"measure":55,"description":56,"timeFrame":28},"Other exploratory endpoints：Change from Baseline in Glucagon","Change from baseline in glucagon level after 12 weeks of treatment.",{"measure":58,"description":59,"timeFrame":28},"Other exploratory endpoints：Change from Baseline in HOMA-β","Change from baseline in homeostatic model assessment of β-cell function (HOMA-β) after 12 weeks of treatment.",{"measure":61,"description":62,"timeFrame":28},"Other exploratory endpoints：Change from Baseline in HOMA-IR","Change from baseline in homeostatic model assessment of insulin resistance (HOMA-IR) after 12 weeks of treatment.",{"allocation":64,"interventionModel":65,"interventionModelDescription":66,"primaryPurpose":6,"observationalModel":66,"timePerspective":66,"maskingInfo":67},"RANDOMIZED","PARALLEL",null,{"masking":68,"maskingDescription":66,"whoMasked":66},"NONE",[70,77],{"label":71,"type":72,"description":73,"interventionNames":74},"Group A：Dapagliflozin + CGM","EXPERIMENTAL","Initiate dapagliflozin therapy in combination with open-label CGM for glucose monitoring",[75,76],"Drug: Dapagliflozin (10mg Tab)","Device: Continuous Glucose Monitoring (CGM)",{"label":78,"type":72,"description":79,"interventionNames":80},"Group B：Dapagliflozin + SMBG","Initiate dapagliflozin therapy in combination with SMBG for fingertip blood glucose monitoring",[75,81],"Other: Self-Monitoring of Blood Glucose (SMBG)",[83,88,93],{"type":84,"name":85,"description":86,"armGroupLabels":87,"otherNames":66},"DRUG","Dapagliflozin (10mg Tab)","10mg，qd",[71,78],{"type":89,"name":90,"description":91,"armGroupLabels":92,"otherNames":66},"DEVICE","Continuous Glucose Monitoring (CGM)","used in Group A, Open-label continuous glucose monitoring (CGM) for glucose monitoring",[71],{"type":6,"name":94,"description":95,"armGroupLabels":96,"otherNames":66},"Self-Monitoring of Blood Glucose (SMBG)","Fingertip self-monitoring of blood glucose (SMBG) using glucometer",[78],[98],{"name":99,"role":100,"phone":101,"phoneExt":66,"email":102},"Yu xia Xiang","CONTACT","15974193674","760809010@qq.com",{"type":104,"investigatorFullName":105,"investigatorTitle":106,"investigatorAffiliation":5,"oldNameTitle":66,"oldOrganization":66},"PRINCIPAL_INVESTIGATOR","Guoping Yang","Chief Pharmacist","100640505",false,"NCT07595289","DP-DCT 1.0：A Comparative Clinical Study on the Effect of Dapagliflozin Combined With CGM Versus SMBG on Glycemic Control in Patients With Type 2 Diabetes Mellitus Based on the DP-DCT Platform","A Comparative Clinical Study on the Effect of Dapagliflozin Combined With CGM Versus SMBG on Glycemic Control in Patients With Type 2 Diabetes Mellitus Based on the DP-DCT Platform","DP DCT","Inclusion Criteria:\n\n* Voluntarily agree to participate in the study and sign the informed consent form; Age between 18 and 60 years (inclusive), both genders; Diagnosed with T2DM within 5 years and have not received any glucose-lowering medication in the past 3 months, with HbA1c ≥ 7% and ≤ 9%; Willing and able to maintain a stable lifestyle in terms of diet and exercise throughout the study period; Able to properly operate a smartphone, CGM, SMBG, smart scale, and smart wristband under the guidance and training of the investigator; During the CGM run-in period, obtain at least 70% data availability from the participants.\n\nExclusion Criteria:\n\n* Diagnosed with or suspected of having type 1 diabetes mellitus, monogenic diabetes, or secondary diabetes; Experienced acute complications of diabetes (diabetic ketoacidosis, hyperosmolar hyperglycemic state, lactic acidosis, etc.) within 3 months prior to screening;\n\nSevere comorbidities or medical history:\n\n1. Poorly controlled hypertension (systolic blood pressure ≥ 160 mmHg and\u002For diastolic blood pressure ≥ 100 mmHg);\n2. Congestive heart failure (NYHA class III-IV);\n3. Severe hepatic or renal impairment (ALT\u002FAST \\> 3 × ULN, eGFR \\\u003C 30 mL\u002Fmin);\n4. Malignant tumors, autoimmune diseases, severe infections, gastroparesis or other severe gastrointestinal diseases, hematological disorders;\n5. History of recurrent genitourinary tract infections; Alcohol abuse or alcoholic liver disease; Known or suspected allergy to SGLT-2 inhibitors (e.g., dapagliflozin) or medical adhesives; Received glucose-lowering medication within the past 3 months; Pregnant or breastfeeding women, or women planning to become pregnant during the study period; Presence of any medical, psychological, social, or geographical factors that, in the investigator's judgment, may compromise participant safety or interfere with the assessment of study outcomes.","ALL","18 Years",{"count":117,"type":118},120,"ESTIMATED","INTERVENTIONAL",[121],"NA","The goal of this clinical trial is to:\n\n1\\) evaluate the feasibility of conducting decentralized clinical trials (DCT) in collaboration with community resources; 2) test the reliability of a self-developed Digital Platform for Decentralized Clinical Trials (DP-DCT); and 3) compare the effect of two different glucose monitoring methods on glycemic control in patients with type 2 diabetes mellitus (T2DM). The study population consists of adults with T2DM who do not have acute diabetic complications.\n\nThe main questions it aims to answer are:\n\nIs it feasible to conduct a DCT in collaboration with community settings across key steps such as participant recruitment, informed consent, drug delivery, and remote monitoring?\n\nCan the DP-DCT platform reliably achieve full electronic integration from participant recruitment to statistical reporting, and automatically generate verified electronic copies of key source data in real time?\n\nIn patients taking dapagliflozin, does continuous glucose monitoring (CGM) lead to a higher rate of glycemic control target achievement compared to traditional self-monitoring of blood glucose (SMBG)?\n\nResearchers will compare the CGM group (dapagliflozin + CGM) and the SMBG group (dapagliflozin + SMBG) to see if there is a difference in the rate of achieving glycemic control targets after 12 weeks of treatment.\n\nParticipants will:\n\nWear a blinded CGM device for 7days before starting treatment (run-in period) to assess eligibility for randomization.\n\nTake dapagliflozin (10 mg once daily) and maintain healthy lifestyle habits.\n\nMonitor their blood glucose using either a CGM device or a traditional glucose meter according to their group assignment.\n\nWear a smart bracelet and use a smart weight scale, with all data automatically uploaded via the DP-DCT platform.\n\nWear a blinded CGM device again for 7 days after the 12-week treatment period (follow-up period).\n\nComplete most study procedures (including informed consent, drug receipt, and follow-up communication) through an online platform without frequent hospital visits, with some tasks supported by community hospitals.",[124],"Type 2 Diabetes Mellitus (T2DM)","NOT_YET_RECRUITING","2026-05-12",{"date":128,"type":129},"2026-05-19","ACTUAL",{"date":131,"type":118},"2026-08-01",{"date":133,"type":118},"2027-08-01",{"name":5,"class":6}]